H.C. Wainwright raised the firm’s price target on Cogent Biosciences to $19 from $13 and keeps a Buy rating on the shares after the company presented updated results for the optimized formulation of bezuclastinib in non-advanced systemic mastocytosis. The firm says bezuclastinib’s reductions in MC-QoL and markers of mast cell burden appear to best Ayvakit. It sees “signs of promise” for bezuclastinib following the new data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Cogent Biosciences price target raised to $18 from $15 at Needham
- Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
- Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
- Cogent Biosciences Launches $225M Private Stock Sale
